No Data
Garden Biology: First quarter report 2025
Zhejiang Garden Biopharmaceutical (300401.SZ): In the first quarter, the net income was 96.5114 million yuan, a year-on-year growth of 5.50%.
On April 17th, Gelonghui reported that Zhejiang Garden Biopharmaceutical (300401.SZ) announced its Q1 2025 report, with revenue of 0.326 billion yuan, a year-on-year decrease of 1.18%; net income attributable to shareholders of the listed company was 96.5114 million yuan, a year-on-year increase of 5.50%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 88.1384 million yuan, a year-on-year increase of 44.42%; EPS was 0.18 yuan.
Zhejiang Garden Biopharmaceutical (300401.SZ): The company's market share of Vitamin D3 products currently stands at 30-40%.
On April 7th, Gelonghui reported that Zhejiang Garden Biopharmaceutical (300401.SZ) recently stated in an investor relations activity that the current market share of its Vitamins D3 products is 30-40%.
A Look At The Intrinsic Value Of Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401)
Garden Creatures: 2024 Annual Report
Garden Creatures: 2024 Annual Report Summary
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Shares May Have Run Too Fast Too Soon